BTIG Research downgraded P3 Health Partners from Buy to Neutral
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 4/1/2024 | Buy → Neutral | BTIG Research | |
| 9/1/2023 | $5.00 | Buy | BTIG Research |
| 6/30/2023 | Market Perform | TD Cowen | |
| 1/4/2022 | Outperform | William Blair |
4 - P3 Health Partners Inc. (0001832511) (Issuer)
4 - P3 Health Partners Inc. (0001832511) (Issuer)
4 - P3 Health Partners Inc. (0001832511) (Issuer)
3 - P3 Health Partners Inc. (0001832511) (Issuer)
4 - P3 Health Partners Inc. (0001832511) (Issuer)
4 - P3 Health Partners Inc. (0001832511) (Issuer)
P3 Health Partners Inc. ("P3") (NASDAQ:PIII), a patient-centered and physician-led population health management company, announced today that Leif Pedersen, an experienced finance, operational and value-based care executive, will join the company as chief financial officer (CFO) effective October 1, 2024. Pedersen succeeds Atul Kavthekar, who will continue as CFO until September 30, 2024, after which he will serve as a Strategic Advisor to the company. Pedersen was most recently Vice President of Finance & CFO Shared Services for Optum Health, a division of UnitedHealth Group. Prior to Optum Health, Pedersen served as Vice President of Finance & CFO IT at DaVita Medical Group. He brings m
P3 Health Partners Inc. ("P3" or the "Company") (NASDAQ:PIII), today named Dr. Aric Coffman as P3's Chief Executive Officer, effective as of May 8, 2024, succeeding Dr. Sherif Abdou, P3's Co-Founder. Dr. Abdou will continue to serve as a Strategic Advisor to P3, and a member of the Company's Board of Directors working closely with Dr. Coffman to ensure a smooth transition. Dr. Coffman is an exceptional physician leader with a proven track record of success in the value-based care sector, most recently as the CEO of Honest Medical Group, a Rubicon Founders portfolio company. He brings over two decades of experience in leading provider organizations in delivering high quality, highly effici
10-Q - P3 Health Partners Inc. (0001832511) (Filer)
8-K - P3 Health Partners Inc. (0001832511) (Filer)
8-K - P3 Health Partners Inc. (0001832511) (Filer)
SC 13G - P3 Health Partners Inc. (0001832511) (Subject)
SC 13D/A - P3 Health Partners Inc. (0001832511) (Subject)
SC 13D/A - P3 Health Partners Inc. (0001832511) (Subject)
Revenue increased 26% year-over-year to $362.1 million Third quarter results were affected by lower risk adjustments, higher medical expenses in the current year, and retroactive adjustments Executing key 2025 initiatives with a focus on improvements in profitability metrics Management to Host Conference Call and Webcast November 12, 2024 at 4:30 PM ET P3 Health Partners Inc. ("P3" or the "Company") (NASDAQ:PIII), a patient-centered and physician-led population health management company, today announced its financial results for the third quarter ended September 30, 2024. "As we execute on our strategic initiatives, we believe P3 will be well-positioned to unlock the value built w
P3 Health Partners Inc. ("P3") (NASDAQ:PIII), a patient-centered and physician-led population health management company, today announced that the Company plans to release its financial results for third quarter 2024 and file its Quarterly Report on Form 10-Q on Tuesday, November 12, 2024. In connection with the release, management will host a conference call to discuss the financial results at 1:30pm PT/ 4:30pm ET the same day. Title & Webcast P3 Health Third Quarter Earnings Conference Call Date & Time November 12, 2024, 4:30pm Eastern Time Conference Call Details Toll-Free 1-833-316-0546 (US) International 1-412-317-0692 Ask to be joined into the P3 Health Partne
Management to Host Conference Call and Webcast August 7, 2024 at 4:30 PM ET P3 Health Partners Inc. ("P3" or the "Company") (NASDAQ:PIII), a patient-centered and physician-led population health management company, today announced its financial results for the second quarter ended June 30, 2024. "In the second quarter, we experienced continued growth in our top line while simultaneously enhancing our balance sheet through a successful capital raise," said Aric Coffman, CEO of P3. "Building on P3's key strengths, I have identified several initiatives during my first 90 days as CEO that will further enhance our capabilities and help achieve sustainable profitability." Second Quarter 2024
P3 Health Partners Inc. ("P3" or the "Company") (NASDAQ:PIII), a patient-centered and physician-led population health management company, today announced the Company will participate in the following upcoming investor conferences: - The 3rd Annual Needham Virtual Healthcare IT 1x1 Conference on Wednesday, November 20, 2024 - The BTIG Digital Health Forum on Monday, November 25, 2024 About P3 Health Partners (NASDAQ:PIII) P3 Health Partners Inc. is a leading population health management company committed to transforming healthcare by improving the lives of both patients and providers. Founded and led by physicians, P3 has an expansive network of more than 3,1
Revenue increased 26% year-over-year to $362.1 million Third quarter results were affected by lower risk adjustments, higher medical expenses in the current year, and retroactive adjustments Executing key 2025 initiatives with a focus on improvements in profitability metrics Management to Host Conference Call and Webcast November 12, 2024 at 4:30 PM ET P3 Health Partners Inc. ("P3" or the "Company") (NASDAQ:PIII), a patient-centered and physician-led population health management company, today announced its financial results for the third quarter ended September 30, 2024. "As we execute on our strategic initiatives, we believe P3 will be well-positioned to unlock the value built w
P3 Health Partners Inc. ("P3") (NASDAQ:PIII), a patient-centered and physician-led population health management company, today announced that the Company plans to release its financial results for third quarter 2024 and file its Quarterly Report on Form 10-Q on Tuesday, November 12, 2024. In connection with the release, management will host a conference call to discuss the financial results at 1:30pm PT/ 4:30pm ET the same day. Title & Webcast P3 Health Third Quarter Earnings Conference Call Date & Time November 12, 2024, 4:30pm Eastern Time Conference Call Details Toll-Free 1-833-316-0546 (US) International 1-412-317-0692 Ask to be joined into the P3 Health Partne
Gainers OneMedNet (NASDAQ:ONMD) shares moved upwards by 118.4% to $1.07 during Thursday's regular session. The market value of their outstanding shares is at $25.5 million. Renovaro (NASDAQ:RENB) stock rose 46.79% to $1.38. The company's market cap stands at $203.5 million. Altamira Therapeutics (NASDAQ:CYTO) shares increased by 29.37% to $1.85. The company's market cap stands at $4.1 million. Purple Biotech (NASDAQ:PPBT) stock rose 23.44% to $0.84. The company's market cap stands at $21.9 million. As per the press release, Q1 earnings came out 2 days ago. P3 Health Partners (NASDAQ:PIII) stock increased by 23.04% to $0.62. The market value of their outstanding shares is at $73.8 millio
P3 Health Partners Inc. (NASDAQ:PIII), a patient- centered and physician-led population health management company (the "Company"), today announced that it has entered into definitive agreements to sell securities in a private placement with certain institutional investors. The lead institutional investors in the private placement are affiliates of Chicago Pacific Founders ("CPF"). The transaction is expected to result in gross proceeds of approximately $42.2 million, including approximately $20.0 million of gross proceeds from purchases by affiliates of CPF, before deducting placement agent fees and offering expenses.The Company plans to use the net proceeds from the financing for working ca
BTIG Research downgraded P3 Health Partners from Buy to Neutral
BTIG Research initiated coverage of P3 Health Partners with a rating of Buy and set a new price target of $5.00
TD Cowen initiated coverage of P3 Health Partners with a rating of Market Perform